BioXcel Therapeutics plans to conduct additional Phase 3 trials for BXCL501 in its TRANQUILITY program to evaluate safety and efficacy data in the at-home setting for the treatment of agitation associated with dementia and bipolar disorders, and is seeking feedback from the FDA on trial design and labeling expansion.